

World Journal of *Gastroenterology*

World J Gastroenterol 2017 June 28; 23(24): 4317-4472



**EDITORIAL**

- 4317 Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C
- 4324 Role of new endoscopic techniques in inflammatory bowel disease management: Has the change come?
Goran L, Negreanu L, Negreanu AM

REVIEW

- 4330 Implication of the Hedgehog pathway in hepatocellular carcinoma
Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F

ORIGINAL ARTICLE**Basic Study**

- 4341 Indole phytoalexin derivatives induce mitochondrialmediated apoptosis in human colorectal carcinoma cells
Tischlerova V, Kello M, Budovska M, Mojzis J
- 4354 Naringenin prevents experimental liver fibrosis by blocking TGF β -Smad3 and JNK-Smad3 pathways
Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P
- 4369 Intestinal anti-inflammatory activity of Ground Cherry (*Physalis angulata* L.) standardized CO₂ phytopharmaceutical preparation
Almeida Junior LD, Quaglio AEV, de Almeida Costa CAR, Di Stasi LC
- 4381 *Maytenus erythroxylon* Reissek (Celastraceae) ethanol extract presents antidiarrheal activity *via* antimotility and antisecretory mechanisms
Formiga RO, Quirino ZGM, Diniz MFFM, Marinho AF, Tavares JF, Batista LM
- 4390 Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation
Lu WW, Zhang H, Li YM, Ji F
- Retrospective Cohort Study**
- 4399 Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer
Sperti C, Gruppo M, Blandamura S, Valmasoni M, Pozza G, Passuello N, Beltrame V, Moletta L

Retrospective Study

- 4407 Risk factors for metachronous gastric carcinoma development after endoscopic resection of gastric dysplasia: Retrospective, single-center study

Moon HS, Yun GY, Kim JS, Eun HS, Kang SH, Sung JK, Jeong HY, Song KS

- 4416 New magnifying endoscopic classification for superficial esophageal squamous cell carcinoma

Kim SJ, Kim GH, Lee MW, Jeon HK, Baek DH, Lee BE, Song GA

- 4422 Procalcitonin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation

Gao Y, Yu KJ, Kang K, Liu HT, Zhang X, Huang R, Qu JD, Wang SC, Liu RJ, Liu YS, Wang HL

Observational Study

- 4428 Healthcare utilization and costs associated with gastroparesis

Wadhwa V, Mehta D, Jobanputra Y, Lopez R, Thota PN, Sanaka MR

- 4437 Variability of anti-human transglutaminase testing in celiac disease across Mediterranean countries

Smarrazzo A, Magazzù G, Ben-Hariz M, Legarda Tamara M, Velmishi V, Roma E, Kansu A, Mičetić-Turk D, Bravi E, Stellato P, Arcidiaco C, Greco L

- 4444 Appropriateness of the study of iron deficiency anemia prior to referral for small bowel evaluation at a tertiary center

Rodrigues JP, Pinho R, Silva J, Ponte A, Sousa M, Silva JC, Carvalho J

Randomized Clinical Trial

- 4454 Comparing reduced-dose sodium phosphate tablets to 2 L of polyethylene glycol: A randomized study

Ako S, Takemoto K, Yasutomi E, Sakaguchi C, Murakami M, Sunami T, Oka S, Kenta H, Okazaki N, Baba Y, Yamasaki Y, Asato T, Kawai D, Takenaka R, Tsugeno H, Hiraoka S, Kato J, Fujiki S

CASE REPORT

- 4462 Case of pediatric traditional serrated adenoma resected *via* endoscopic submucosal dissection

Kondo S, Mori H, Nishiyama N, Kondo T, Shimono R, Okada H, Kusaka T

- 4467 Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature

Zheng SM, Zhou DJ, Chen YH, Jiang R, Wang YX, Zhang Y, Xue HL, Wang HQ, Mou D, Zeng WZ

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Christian Martin Grieser, MD, PhD, Associate Professor, Doctor, Center for Modern Diagnostics, Schwachhauser Heerstr. 63a, Bremen 28209, Germany

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Cui-Hong Wang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Yuan Qi*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
June 28, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Retrospective Study

Procalcitonin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation

Yang Gao, Kai-Jiang Yu, Kai Kang, Hai-Tao Liu, Xing Zhang, Rui Huang, Jing-Dong Qu, Si-Cong Wang, Rui-Jin Liu, Yan-Song Liu, Hong-Liang Wang

Yang Gao, Xing Zhang, Rui Huang, Jing-Dong Qu, Si-Cong Wang, Rui-Jin Liu, Hong-Liang Wang, Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang Province, China

Kai-Jiang Yu, Hai-Tao Liu, Yan-Song Liu, Department of Critical Care Medicine, the Cancer Hospital of Harbin Medical University, Harbin 150081, Heilongjiang Province, China

Kai-Jiang Yu, Institute of Critical Care Medicine in Sino Russian Medical Research Center of Harbin Medical University, Harbin 150081, Heilongjiang Province, China

Kai Kang, Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China

Author contributions: Gao Y and Yu KJ contributed equally to this work; Gao Y, Yu KJ, Kang K and Wang HL carried out the studies, participated in data collection, and drafted the manuscript; Liu HT, Zhang X, Huang R, Qu JD, Wang SC, Liu RJ and Liu YS performed the statistical analyses and participated in study design; all authors read and approved the final manuscript.

Supported by National Natural Science Foundation of China, No. 81571871.

Institutional review board statement: The study was approved by the Ethics Committee of Harbin Medical University.

Informed consent statement: All clinical data were collected with informed consent obtained from study participants.

Conflict-of-interest statement: All authors declare that they have no any conflicts of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,

which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Hong-Liang Wang, MD, Department of Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Harbin 150086, Heilongjiang Province, China. icuwanghongliang@163.com
Telephone: +86-21-57643271
Fax: +86-21-57643271

Received: March 1, 2017

Peer-review started: March 2, 2017

First decision: April 10, 2017

Revised: April 19, 2017

Accepted: May 19, 2017

Article in press: May 19, 2017

Published online: June 28, 2017

Abstract

AIM

To assess the accuracy of serum procalcitonin (PCT) as a diagnostic marker in verifying upper and lower gastrointestinal perforation (GIP).

METHODS

This retrospective study included 46 patients from the surgical intensive care unit (ICU) of the Second Affiliated Hospital of Harbin Medical University who were confirmed to have GIP between June 2013 and December 2016. Demographic and clinical patient data were recorded on admission to ICU. Patients were divided into upper ($n = 19$) and lower ($n = 27$) GIP groups according to the perforation site (above

or below Treitz ligament). PCT and WBC count was obtained before laparotomy and then compared between groups. Meanwhile, the diagnostic accuracy of PCT was analyzed.

RESULTS

Patients with lower GIP exhibited significantly higher APACHE II score, SOFA score and serum PCT level than patients with upper GIP ($P = 0.017$, 0.004 , and 0.001 , respectively). There was a significant positive correlation between serum PCT level and APACHE II score or SOFA score ($r = 0.715$ and $r = 0.611$, respectively), while there was a significant negative correlation between serum PCT level and prognosis ($r = -0.414$). WBC count was not significantly different between the two groups, and WBC count showed no significant correlation with serum PCT level, APACHE II score, SOFA score or prognosis. The area under the receiver operating characteristic curve of PCT level to distinguish upper or lower GIP was 0.778. Patients with a serum PCT level above 17.94 ng/dL had a high likelihood of lower GIP, with a sensitivity of 100% and a specificity of 42.1%.

CONCLUSION

Serum PCT level is a reliable and accurate diagnostic marker in identifying upper or lower GIP before laparotomy.

Key words: Procalcitonin; White blood cell count; Gastrointestinal perforation; Sepsis; APACHE II score; SOFA score

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Procalcitonin (PCT) is a rapid, reliable and accurate predictive marker and contributes to assisting the clinicians in identifying upper or lower gastrointestinal perforation (GIP) before laparotomy, and it can be used as a useful supplementary tool for early clinical judgment of perforation site. The results showed that patients with lower GIP exhibited significantly higher APACHE II score, SOFA score and serum PCT level than patients with upper GIP, which might be related to the differences in bacterial load and the severity of sepsis between upper and lower GIP.

Gao Y, Yu KJ, Kang K, Liu HT, Zhang X, Huang R, Qu JD, Wang SC, Liu RJ, Liu YS, Wang HL. Procalcitonin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation. *World J Gastroenterol* 2017; 23(24): 4422-4427 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i24/4422.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i24.4422>

INTRODUCTION

Gastrointestinal perforation (GIP) is one of the most

common acute abdominal diseases in department of general surgery. As a life-threatening disease with a high mortality rate, especially for elderly people, GIP could easily lead to shock and usually needs active rescue in the intensive care unit (ICU) and emergency laparotomy^[1]. In general, GIP is related to many factors such as older age, diabetes, antecedent diverticulitis, glucocorticoid therapy, usage of non-steroidal anti-inflammatory drugs (NSAIDs) and so on^[2-4]. It is still a challenge to accurately predict upper or lower GIP before laparotomy, despite increased available clinical and biological variables. Early diagnosis of perforation site has beneficial effects on operative procedure, selection of antibiotics and even judgement of the severity of infection and prognosis.

Serum procalcitonin (PCT) concentration was discovered to be significantly higher in patients with bacterial and fungal infections, and sepsis first in 1993^[5], which has been proved to be a rapid, reliable and accurate diagnostic marker and is used to identify infectious and non-infectious diseases now^[6-8]. Sepsis could promote the secretion of PCT through stimulating various types of cells in a variety of tissues^[9], which is typically produced by C cells of the thyroid. More importantly, PCT concentration is related to bacterial load^[10], the severity of sepsis^[11], and even prognosis^[12,13]. Owing to different perforation sites and contents, the severity of sepsis and bacterial load are obviously different, especially when comparing upper and lower GIP. We hypothesized that, due to fewer bacteria, the severity of sepsis caused by upper GIP was lower than that caused by lower GIP, which could be reflected by serum PCT level. Thus, serum PCT level might be a useful supplementary tool for clinical judgment of perforation site.

So far, the evidence regarding the diagnostic validity and accuracy of PCT in predicting upper or lower GIP is lacking. To the best of our knowledge, few studies have formally assessed its role in this area. In this retrospective study, serum PCT level was evaluated as a diagnostic marker in distinguishing upper or lower GIP before laparotomy. To our knowledge, this study is the first to evaluate the role of PCT in predicting upper or lower GIP before laparotomy as a useful supplementary tool.

MATERIALS AND METHODS

Study design

The current study is a retrospective study performed in the surgical ICU of the Second Affiliated Hospital of Harbin Medical University (Harbin, China). Patients were enrolled from June 2013 to December 2016. The study protocol was approved by the ethics committee.

Study population

Patients who met the following criteria were included:

Table 1 Baseline data of patients

	Upper <i>n</i> = 19	Lower <i>n</i> = 27	<i>t</i> value	<i>P</i> value
Age	58.84	67.59	-2.280	0.028
Gender				
Male	7	14	1.013	0.314
Female	12	13		
Height	168.47	165.37	1.316	0.195
Weight	63.42	58.37	1.589	0.119
BMI	22.27	21.21	1.176	0.246
APACHEII	12.47	18.15	-2.477	0.017
SOFA	5.84	9.33	-3.041	0.004
PCT	33.26	40.73	-3.079	0.001
WBC	13.67	11.27	1.105	0.275

APACHE II: Acute physiology and chronic health evaluation II; SOFA: Sequential organ failure assessment score.

(1) ICU admission; (2) patients were definitely diagnosed with GIP by laparotomy; (3) serum PCT level and WBC count were detected before laparotomy; and (4) patients aged > 18 years. Patients who met following criteria were excluded: (1) uncertain perforation site; (2) pregnant or breast-feeding women; (3) being on blood purification treatment; and (4) those receiving antibiotic therapy before ICU admission. In addition, patients with incomplete medical records were also excluded. All enrolled patients were treated by same experienced physicians.

Diagnosis of GIP

GIP was defined as the destruction of integrity of the digestive tract, *i.e.*, a complete non-traumatic penetration of the wall of the esophagus, stomach, small or large bowel^[2]. Patients were divided into upper and lower GIP groups according to the perforation site (above or below Treitz ligament). Owing to the complexity of GIP diagnosis, a careful and thorough clinical examination was necessary.

Serum PCT level and WBC count measurement

Serum PCT level and WBC count were measured following ICU admission immediately before laparotomy. Mini VIDAS (Hain Lifescience GmbH; Nehren, Germany) was applied to measure serum PCT level.

Data collection

Baseline data: Gender, age, height, weight, body mass index (BMI), prognosis, acute physiology and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score and perforation site were obtained from patient medical records.

Demographic and clinical data of selected patients were recorded on admission to SICU with blood samples taken for measurement of serum PCT level and WBC count immediately. APACHE II score and SOFA score were calculated using data collected from

Table 2 Correlation analysis

	APACHEII	SOFA	PCT	WBC	Prognosis
PCT	0.715 < 0.001	0.611 < 0.001	1.000 < 0.001	-0.143 0.342	-0.414 0.004
WBC	-0.242 0.105	-0.033 0.829	-0.143 0.342	1.000 0.112	0.112 0.457

PCT: Procalcitonin.

the first 24 h after admission.

Statistical analysis

Data are described as the mean \pm SD and SPSS 13.0 (SPSS Inc., Chicago, IL, United States) was used for statistical analyses. To compare baseline data between groups, independent sample *t* test and χ^2 test were employed. Independent sample *t* test was used to compare APACHE II score, SOFA score and WBC count between groups. Owing to non-normality, serum PCT level between groups was analyzed by the Mann-Whitney rank sum test. Correlation between parameters was analyzed by Pearson or Spearman correlation. Area under the receiver operating characteristic (ROC) curve was calculated to evaluate the predictive value of PCT and to determine optimal cut-off value for distinguishing between upper and lower GIP before laparotomy. *P*-values < 0.05 were considered statistically significant.

RESULTS

Baseline data of patients

A total of 46 patients were enrolled in this retrospective study who underwent serum PCT level and WBC count measurement following ICU admission immediately before laparotomy. In all patients, GIP was proved by laparotomy. Nineteen patients were included into the upper GIP group, while the rest patients in the lower GIP group. As shown in Table 1, no significant differences were observed in baseline data with the exception of age (*P* = 0.028).

Diagnostic value of serum PCT level and WBC count

Patients with lower GIP exhibited significantly higher APACHE II score, SOFA score and serum PCT level than patients with upper GIP (*P* = 0.017, 0.004, and 0.001, respectively). However, WBC count showed no significant difference between the two groups, and WBC count showed no significant correlation with serum PCT level, APACHE II score, SOFA score or prognosis (Table 2). The area under the ROC curve of PCT level to distinguish upper and lower GIP was 0.778 (Figure 1). Patients with a serum PCT level above 17.94 ng/dL had a high likelihood of lower GIP, with a sensitivity of 100% and a specificity of 42.1% (Table 3).




Figure 1 ROC curve shows that the area under the curve of procalcitonin level to distinguish upper or lower gastrointestinal perforation is 0.778.

DISCUSSION

PCT is a prepropeptide precursor of calcitonin, which had been proved to be a sensitive and specific predictive marker for bacterial infection^[14,15], and thus was used to guide antibacterial therapy and reduce its length^[16-19], which is not affected by hepatic or renal dysfunction^[20-22]. PCT has many advantages of an ideal marker for routine clinical application, including simplicity, accuracy, specificity, stability and availability^[23]. However, little is known on the predictive value of PCT in judging perforation site before laparotomy. We speculated that, when upper or lower GIP happens, they are different in bacterial load and the severity of sepsis owing to the leakage of different digestive tract contents, which could be reflected by serum PCT level. Antibiotic therapy might have an impact on bacterial load and even serum PCT level, therefore, patients who had used antibiotics before ICU admission were excluded^[24].

APACHE II score and SOFA score are usually applied to evaluate the severity of disease^[25], especially suitable for critically ill adult patients in ICU, which are closely related to mortality^[25-29]. Therefore, in our study, they were chosen to assess the degree of illness. In particular, SOFA score was an important part of sepsis diagnosis in The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)^[30].

The results of the present study showed that patients with lower GIP exhibited significantly higher APACHE II score, SOFA score and serum PCT level than patients with upper GIP, which might be related to the differences in bacterial load and the severity of sepsis between upper and lower GIP. In contrast, our findings did not show a significant difference between the two groups regarding WBC count. In other words, WBC count did not have a predictive value for sepsis, which is in accordance with previous studies^[31]. Further correlation analysis showed that there was

Table 3 Area under the receiver operating characteristic curve

Area	Std. Error	Asymptotic Sig.	Asymptotic 95%CI	
			Lower bound	Upper bound
0.778	0.077	0.001	0.628	0.928

a significant positive correlation between serum PCT level and APACHE II score or SOFA score, and a significant negative correlation between serum PCT level and prognosis. By analyzing the ROC curve, an optimal cut-off value was selected as a predictive value to distinguish between upper and lower GIP before laparotomy.

There were several limitations in the present study. First, patients were selected from a single center, which made the evidence level for this study relatively low. Second, the sample size was relatively small. Thus, experiments with larger sample size are needed to verify our findings in the future. At last, this study only concerned serum PCT level measured immediately after ICU admission and before laparotomy, but lacked of dynamic observation of changes in serum PCT level after laparotomy.

In conclusion, PCT is a rapid, reliable and accurate predictive marker and contributes to assisting clinicians toward identifying upper or lower GIP before laparotomy, which can be used as a useful supplementary tool for early clinical judgment of perforation site.

ACKNOWLEDGMENTS

We thank the participants and colleagues from the SICU of the Second Affiliated Hospital of Harbin Medical University, and all the people who offered the advice and help to this study.

COMMENTS

Background

Gastrointestinal perforation (GIP) is one of the most common acute abdominal diseases in department of general surgery with high mortality rates, which could easily lead to shock and needs rescue therapy in the intensive care unit. It is still a challenge to accurately predict upper or lower GIP before laparotomy, despite increased available clinical and biological variables. Serum procalcitonin (PCT) concentration is related to bacterial load as well as the severity of sepsis, and even prognosis. Thus, the authors hypothesized that, due to fewer bacteria, the severity of sepsis caused by upper GIP is lower than that caused by lower GIP, which could be reflected by serum PCT level.

Research frontiers

At present, the research on PCT has mainly focused on the following aspects: being used as a predictive marker for bacterial infection, distinguishing between bacterial and non-bacterial infections, guiding antibacterial therapy and reducing its length and so on. But so far the evidence regarding the diagnostic validity and accuracy of PCT in predicting upper or lower GIPs is lacking. To the best of our knowledge, few studies have formally assessed its role in this area.

Innovations and breakthroughs

This study is the first to evaluate the role of PCT in predicting upper or

lower GIP before laparotomy as a useful supplementary tool. This study has confirmed that PCT is a rapid, reliable and accurate predictive marker and can be used for early clinical judgment of perforation site.

Applications

When upper or lower GIP happens, they are different in bacterial load and the severity of sepsis owing to leakage of different digestive tract contents, which could be reflected by serum PCT level. Therefore, PCT contributes to assisting clinicians toward identifying upper or lower GIP before laparotomy, which has beneficial effects on operative procedure, selection of antibiotics and even judgement of the severity of infection and prognosis.

Terminology

PCT is a prepropeptide precursor of calcitonin, and its level was discovered to be significantly higher in patients with bacterial and fungal infections, and sepsis first in 1993. GIP was defined as the destruction of integrity of the digestive tract, *i.e.*, a complete non-traumatic penetration of the wall of the esophagus, stomach, small or large bowel. Patients were divided into upper and lower GIP groups according to the perforation site (above or below Treitz ligament).

Peer-review

This is an interesting study about the procalcitonin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation. In this retrospective study, the authors included 46 patients from the SICU of the Second Affiliated Hospital of Harbin Medical University who were confirmed to have GIP between June 2013 and December 2016. There was a significant positive correlation between serum PCT level and APACHE II score or SOFA score, while there was a significant negative correlation between serum PCT level and Prognosis. Patients with a serum PCT level above 17.94 ng/dL had a high likelihood of lower GIP, with a sensitivity of 100% and a specificity of 42.1%.

REFERENCES

- 1 **Domínguez-Comesaña E**, Ballinas-Miranda JR. Procalcitonin as a marker of intra-abdominal infection. *Cir Cir* 2014; **82**: 231-239 [PMID: 25312325]
- 2 **Závada J**, Lunt M, Davies R, Low AS, Mercer LK, Galloway JB, Watson KD, Symmons DP, Hyrich KL. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. *Ann Rheum Dis* 2014; **73**: 252-255 [PMID: 23644671 DOI: 10.1136/annrheumdis-2012-203102]
- 3 **Xie F**, Yun H, Bernatsky S, Curtis JR. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. *Arthritis Rheumatol* 2016; **68**: 2612-2617 [PMID: 27213279 DOI: 10.1002/art.39761]
- 4 **Curtis JR**, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, Delzell E. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. *Arthritis Rheum* 2011; **63**: 346-351 [PMID: 20967860 DOI: 10.1002/art.30107]
- 5 **Assicot M**, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* 1993; **341**: 515-518 [PMID: 8094770]
- 6 **Yang Y**, Xie J, Guo F, Longhini F, Gao Z, Huang Y, Qiu H. Combination of C-reactive protein, procalcitonin and sepsis-related organ failure score for the diagnosis of sepsis in critical patients. *Ann Intensive Care* 2016; **6**: 51 [PMID: 27287669 DOI: 10.1186/s13613-016-0153-5]
- 7 **Arora R**, Campbell JP, Simon G, Sahni N. Does serum procalcitonin aid in the diagnosis of bloodstream infection regardless of whether patients exhibit the systemic inflammatory response syndrome. *Infection* 2016; Epub ahead of print
- 8 **Simon L**, Saint-Louis P, Amre DK, Lacroix J, Gauvin F. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. *Pediatr Crit Care Med* 2008; **9**: 407-413 [PMID: 18496408 DOI: 10.1097/PCC.0b013e31817285a6]
- 9 **Schneider HG**, Lam QT. Procalcitonin for the clinical laboratory: a review. *Pathology* 2007; **39**: 383-390 [PMID: 17676478 DOI: 10.1080/00313020701444564]
- 10 **van Nieuwkoop C**, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, van Dissel JT. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. *Crit Care* 2010; **14**: R206 [PMID: 21083886 DOI: 10.1186/cc9328]
- 11 **Jiang L**, Feng B, Gao D, Zhang Y. Plasma concentrations of copeptin, C-reactive protein and procalcitonin are positively correlated with APACHE II scores in patients with sepsis. *J Int Med Res* 2015; **43**: 188-195 [PMID: 25691533 DOI: 10.1177/0300060514561136]
- 12 **Liu D**, Su LX, Guan W, Xiao K, Xie LX. Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis. *Respirology* 2016; **21**: 280-288 [PMID: 26662169 DOI: 10.1111/resp.12704]
- 13 **Jain S**, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, Biswas A, Sood S, Goel M, Das M, Vishnubhatla S, Khan N. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. *BMC Res Notes* 2014; **7**: 458 [PMID: 25034373 DOI: 10.1186/1756-0500-7-458]
- 14 **Takakura Y**, Hinoi T, Egi H, Shimomura M, Adachi T, Saito Y, Tanimine N, Miguchi M, Ohdan H. Procalcitonin as a predictive marker for surgical site infection in elective colorectal cancer surgery. *Langenbecks Arch Surg* 2013; **398**: 833-839 [PMID: 23784676 DOI: 10.1007/s00423-013-1095-0]
- 15 **Schlattmann P**, Brunkhorst FM. Procalcitonin as a diagnostic marker for sepsis. *Lancet Infect Dis* 2014; **14**: 189 [PMID: 24571977 DOI: 10.1016/s1473-3099(13)70325-6]
- 16 **de Jong E**, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loeff BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis* 2016; **16**: 819-827 [PMID: 26947523 DOI: 10.1016/s1473-3099(16)00053-0]
- 17 **Prkno A**, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. *Crit Care* 2013; **17**: R291 [PMID: 24330744 DOI: 10.1186/cc13157]
- 18 **Oliveira CF**, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, Nobre V. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. *Crit Care Med* 2013; **41**: 2336-2343 [PMID: 23921272 DOI: 10.1097/CCM.0b013e31828e969f]
- 19 **Hohn A**, Schroeder S, Gehrt A, Bernhardt K, Bein B, Wegscheider K, Hochreiter M. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. *BMC Infect Dis* 2013; **13**: 158 [PMID: 23547790 DOI: 10.1186/1471-2334-13-158]
- 20 **Lin KH**, Wang FL, Wu MS, Jiang BY, Kao WL, Chao HY, Wu JY, Lee CC. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. *Diagn Microbiol Infect Dis* 2014; **80**: 72-78 [PMID: 24974271 DOI: 10.1016/j.diagmicrobio.2014.03.029]
- 21 **Rau BM**, Frigerio I, Büchler MW, Wegscheider K, Bassi C, Puolakkainen PA, Beger HG, Schilling MK. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. *Arch Surg* 2007; **142**: 134-142 [PMID: 17309964 DOI: 10.1001/archsurg.142.2.134]
- 22 **Meisner M**, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function.

- Eur J Anaesthesiol* 2001; **18**: 79-87 [PMID: 11270029]
- 23 **Walker C.** Procalcitonin-guided antibiotic therapy duration in critically ill adults. *AACN Adv Crit Care* 2005; **26**: 99-106 [PMID: 25898876 DOI: 10.1097/nci.0000000000000079]
 - 24 **Hoebner SH,** van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. *Clin Microbiol Infect* 2015; **21**: 474-481 [PMID: 25726038 DOI: 10.1016/j.cmi.2014.12.026]
 - 25 **Naved SA,** Siddiqui S, Khan FH. APACHE-II score correlation with mortality and length of stay in an intensive care unit. *J Coll Physicians Surg Pak* 2011; **21**: 4-8 [PMID: 21276376 DOI: 10.2011/jcpsp.0408]
 - 26 **Stevens V,** Lodise TP, Tsuji B, Stringham M, Butterfield J, Dodds Ashley E, Brown K, Forrest A, Brown J. The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *Infect Control Hosp Epidemiol* 2012; **33**: 558-564 [PMID: 22561710 DOI: 10.1086/665731]
 - 27 **De Freitas ER.** Profile and severity of the patients of intensive care units: prospective application of the APACHE II index. *Rev Lat Am Enfermagem* 2010; **18**: 317-323 [PMID: 20721418]
 - 28 **Al Tehewy M,** El Houssinie M, El Ezz NA, Abdelkhalik M, El Damaty S. Developing severity adjusted quality measures for intensive care units. *Int J Health Care Qual Assur* 2010; **23**: 277-286 [PMID: 20535900 DOI: 10.1108/09526861011029343]
 - 29 **Rocker G,** Cook D, Sjøkvist P, Weaver B, Finfer S, McDonald E, Marshall J, Kirby A, Levy M, Dodek P, Heyland D, Guyatt G. Clinician predictions of intensive care unit mortality. *Crit Care Med* 2004; **32**: 1149-1154 [PMID: 15190965]
 - 30 **Singer M,** Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; **315**: 801-810 [PMID: 26903338 DOI: 10.1001/jama.2016.0287]
 - 31 **Seigel TA,** Cocchi MN, Saliciccioli J, Shapiro NI, Howell M, Tang A, Donnino MW. Inadequacy of temperature and white blood cell count in predicting bacteremia in patients with suspected infection. *J Emerg Med* 2012; **42**: 254-259 [PMID: 20674238 DOI: 10.1016/j.jemermed.2010.05.038]

P- Reviewer: Chadokufa S, Chamberlain MC **S- Editor:** Qi Y
L- Editor: Wang TQ **E- Editor:** Wang CH





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

